# What is glutathione?

> Glutathione is a three-amino-acid peptide that cells make to neutralize oxidants, sold as a supplement and given by drip, injection or inhalation; it is not FDA-approved. Its largest trials found it did not prevent kidney injury from X-ray dye, skin-lightening trials are small, and in 2026 contaminated compounded injections were linked to illness in at least four states.

The journal is published by Rovere, a telehealth service that sells some of the treatments discussed here. Articles are general information, not medical advice. Only a licensed clinician can say whether a treatment is right for you.

- Topic: Compounds
- Web page: https://roverehealth.com/journal/glutathione

## Key points

- Glutathione is a peptide of three amino acids, glutamate, cysteine and glycine, made in nearly every cell. Inside cells, enzymes use it to neutralize peroxides and to inactivate drugs and toxins.
- Glutathione is not FDA-approved. In 2022 FDA staff advised against listing it for pharmacy compounding, but FDA advisers voted 8 to 5 for listing. Meanwhile, the FDA says it does not intend to act against such compounding under set conditions.
- The largest trials, of 396 to 825 heart patients, found IV glutathione did not prevent kidney injury from X-ray dye. Parkinson disease trials found no clear benefit, the largest chemotherapy nerve-damage trial found none, and cystic fibrosis results were mixed.
- In small trials, swallowed or skin-applied glutathione sometimes lowered pigment readings more than placebo; the only placebo-controlled IV lightening trial, of a mixed product, found no clear difference. In 2018 the FDA called injectable skin lighteners potentially unsafe and ineffective.
- Reported harms include severe allergic reactions to IV glutathione, airway narrowing when people with asthma inhale it, and liver injury. In 2026, contaminated compounded glutathione injections were linked to illness in over 25 people in at least four states.

## At a glance

| Compound | Kind | How it is taken | FDA status | Research in people |
| --- | --- | --- | --- | --- |
| Glutathione (also: GSH, reduced glutathione, L-glutathione, gamma-L-glutamyl-L-cysteinylglycine) | Antioxidant the body makes; a chain of three amino acids (peptide) | Infusion or injection into a vein; injection into a muscle or under the skin; by mouth; inhaled; nasal spray; on the skin; rectal suppository | Not FDA-approved for any use; listed as under evaluation (Category 1) on the FDA’s list of substances nominated for pharmacy compounding, updated May 14, 2026. (checked 2026-11-14) | Large trials in people. The largest randomized trials, of 396 to 825 heart patients in China, found IV glutathione did not prevent kidney injury from X-ray dye, a different use from skin lightening. Skin-lightening trials were small and mixed. |

## What it is

Glutathione is a peptide, a short chain of amino acids, made of three: glutamate, cysteine and glycine. Nearly every cell makes it to defend against oxidative stress, the damage done by reactive forms of oxygen. The name usually means reduced glutathione. Oxidized glutathione, two molecules joined together, is the form left after glutathione neutralizes an oxidant. [1, 2]

Glutathione is sold in the United States as a dietary supplement. In 2022, FDA staff found medical spas across the country offering glutathione injections and infusions for skin lightening. [2]

## How it works

Inside cells, enzymes use glutathione to neutralize hydrogen peroxide and other harmful by-products of normal metabolism, and to inactivate drugs, pollutants and other foreign chemicals. [1, 2]

An enzyme in the gut and liver (gamma-glutamyl transferase) breaks swallowed glutathione apart. In a 1992 study of 7 healthy volunteers, a single large swallowed dose did not raise blood glutathione over the next four and a half hours. Levels in red blood cells did not change over 4 weeks in a 2011 trial of 40 adults but rose over 6 months in a 2015 trial of 54 adults. They fell back within a month of stopping. [3, 4, 5]

Given into a vein, it leaves the blood quickly: in a study of 10 healthy volunteers, its level halved about every 15 minutes. [2]

A 2014 trial report and a 2016 review describe how glutathione might lighten skin, based on lab studies. It may block tyrosinase, an enzyme needed to make the pigment melanin, and shift pigment cells toward red melanin rather than brown. [6, 7]

## How it is taken

Trials have given glutathione into a vein (intravenously, or IV), by mouth, as an inhaled mist, as a nasal spray and on the skin. Compounders have prepared it for injection into a muscle or under the skin and as suppositories, the FDA’s 2022 review found. [8, 5, 9, 10, 6, 11, 2]

## What the research in people shows

In 2022, FDA staff reviewed the evidence for glutathione in 24 proposed uses and found no information or too little evidence that it works for any. Some evidence may support skin lightening, they said, but no specific group or dose had been established. [2]

The largest randomized trials of glutathione, in which people were assigned by chance, tested it in China to prevent kidney injury from the X-ray dye used in heart procedures. None reduced kidney injury. One, a 2015 trial of 825 people, compared IV glutathione with a placebo, a dummy infusion. Two others, of 505 people aged 75 or older (2015) and 396 older people with diabetes (2020), used no placebo. [12, 13, 14]

Other randomized, placebo-controlled trials of glutathione, oldest first. [8, 9, 15, 16, 17, 10, 18, 2]

| How it was given, and the use | Who took part, and for how long | What it found |
| --- | --- | --- |
| Into a vein, for Parkinson disease (2009) | 21 people; 4 weeks | Symptom scores did not differ clearly from placebo |
| Inhaled, for cystic fibrosis (2013) | 153 people aged 8 and older; 6 months | Missed its main lung-function goals despite a gain over placebo at 3 months; no fewer flare-ups or better quality of life |
| Into a vein, to prevent chemotherapy nerve damage (N08CA, 2014) | 185 people on the cancer drugs paclitaxel and carboplatin; at least 12 weeks of treatment | No less nerve damage than with placebo; no difference in time until the cancer worsened |
| Inhaled, for cystic fibrosis (2015) | 105 adults and children; 12 months | Missed its main lung-function goal; lung function rose from where it started only in people with moderate lung disease, and children walked farther in a 6-minute test |
| By mouth, for cystic fibrosis (2015) | 44 children up to age 10; 6 months | Growth and a gut-inflammation marker improved more than with placebo; FDA staff noted that more of the placebo group had a genetic type linked to more severe disease |
| Nasal spray, for Parkinson disease (2017) | 45 people; 3 months | All groups improved, placebo included, and neither glutathione group did better; one person given glutathione developed heart muscle disease (cardiomyopathy) |
| By mouth, for cystic fibrosis (2020) | 58 children aged 2 to 10 who finished; 6 months | No effect on growth or on markers of inflammation |

A 2019 Cochrane systematic review, which gathers all trials meeting rules set in advance, pooled the two inhaled trials, with 258 people. Lung function was probably better than with placebo at three months; at six, results differed by measure. The reviewers concluded that inhaled and oral glutathione appear to improve lung function, but that intensive antibiotic and other treatments make any effect hard to judge. [19]

Several small trials in the 1990s and 2000s reported less nerve damage when IV glutathione was given with the platinum cancer drugs cisplatin or oxaliplatin; the FDA’s review called the results mixed. A 1997 randomized trial of 151 women with ovarian cancer also reported fewer nerve symptoms with glutathione. [2, 20]

A 2026 systematic review of 25 randomized trials of glutathione and related compounds found that none clearly reduced nerve damage. It linked glutathione to fewer severe cases but called this preliminary. The American Society of Clinical Oncology’s 2020 guideline does not recommend any medicine for preventing this nerve damage. [21, 22]

## Skin-lightening trials

A 2012 Thai trial gave 60 medical students glutathione capsules or a placebo for 4 weeks. Pigment readings from a light-based meter fell at all six measured sites with glutathione, but by more than with placebo at only two. FDA staff noted the trial did not show whether the readings matched changes visible to the eye. [23, 2]

A 2017 trial by the same group gave 60 women capsules of reduced glutathione, oxidized glutathione or a placebo for 12 weeks. Pigment readings tended to be lower with both forms, but the differences could have been due to chance. The company that supplied the capsules paid for the trial. [24, 2]

A 2014 trial had 30 women apply oxidized glutathione lotion to one side of the face and a placebo lotion to the other for 10 weeks. Pigment readings were lower on the treated side. Three of the four authors worked for the company that made the oxidized glutathione. A 2021 trial of 46 people over 8 weeks reported more lightening with glutathione on the skin and by mouth together than with placebo. [6, 11]

A 2025 systematic review of 10 years of studies found only one placebo-controlled trial of IV glutathione for skin lightening. In that 2016 trial, 50 women received an IV product containing glutathione, vitamin C and collagen, or salt water, for 6 weeks, and 32 finished. Lightening was not clearly more common with the product, and it faded after treatment stopped, FDA staff reported. [25, 2]

The 2025 review rated swallowed and skin-applied glutathione as moderately effective for lightening but called both unsustainable. It judged side effects minimal for skin-applied forms and substantial for swallowed ones, and said IV glutathione should not be used, citing side effects and lack of effect. The FDA’s review found no data that lightening from glutathione helps treat any skin disease, such as melasma, which causes patches on the face. [25, 2, 26]

## Side effects and risks

FDA staff listed anaphylaxis, a life-threatening allergic reaction, along with liver injury and severe wheezing as serious safety issues with glutathione. In FDA adverse event reports from 2000 through 2021, they found 17 cases linked to glutathione, 15 in the United States. Seven described anaphylaxis or other allergic reactions, five of them after IV use. In one US case, a woman had anaphylaxis during an infusion and again when given glutathione 10 days later, the second time needing CPR. [2]

Inhaling glutathione can narrow the airways of people with asthma. In a 1997 trial, 8 people with mild asthma inhaled glutathione or a placebo a week apart. On average glutathione narrowed their airways, severely in one person, and it caused cough in four and breathlessness in three. [27, 2]

In the 2016 IV skin trial, 9 of the 25 women given the product stopped because of severe side effects, FDA staff reported. Eight stopped for abnormal liver tests and one for anaphylaxis. Every woman given the product reported side effects, and none given salt water did. [2]

Two of 60 women in the 2017 capsule trial stopped because of raised liver test results, which returned to normal within a few weeks. The paper did not say which group they were in. A Japanese case report described liver injury in a man with Parkinson disease after five months of IV glutathione alongside other medicines; it resolved after they were stopped. [24, 2]

The Philippines’ drug regulator has reported thyroid problems, kidney problems and severe, potentially fatal skin reactions after IV glutathione. FDA staff, who relayed these reports, said it is unclear whether glutathione itself or other factors, such as other ingredients, caused particular IV reactions. [2]

The FDA has warned that injectable skin lighteners, including products containing glutathione, are potentially unsafe and ineffective, and may contain unknown harmful ingredients or contaminants. The warning was first issued in 2015 and last revised in 2018. [26, 28]

The FDA’s review linked swallowed glutathione mainly to stomach and gut side effects. In the 6-month 2015 trial, no serious side effects were reported, and minor ones were about as common with placebo. [2, 5]

A 2009 trial of 27 people with colorectal cancer found IV glutathione lowered the overall blood levels of the cancer drug oxaliplatin. The authors concluded that this did not impair the drug, but FDA staff said it may affect how well the drug works. Higher glutathione levels are often linked to cancer cells resisting chemotherapy, they added. [29, 2]

## FDA status

No glutathione drug is FDA-approved for any use. An approved eye irrigation solution contains oxidized glutathione, which the FDA treats as a different substance. Nor does glutathione have an official US Pharmacopeia quality standard as a drug ingredient (a drug monograph). [2, 30, 46]

State-licensed pharmacies compound under section 503A of federal law. They may use a raw ingredient (a bulk drug substance) that has such a monograph or is part of an FDA-approved drug. An ingredient that is neither must be on the FDA’s list of extra permitted ingredients, the 503A bulks list. Glutathione meets none of these. [31, 32, 30]

FDA staff reviewed glutathione for that list and in May 2022 recommended against adding it, citing serious safety issues, especially with injected and inhaled forms, and too little evidence that it works. On June 8, 2022, the FDA’s Pharmacy Compounding Advisory Committee, a panel of outside advisers, voted 8 to 5, with 1 abstention, for adding it. Yes voters cited patient access and the ingredient’s stability; no voters cited too little evidence that it works. [2, 30]

The FDA has not decided. Its list of nominated substances, updated May 14, 2026, places glutathione in Category 1, under evaluation. Until it decides, the FDA says it does not intend to act against compounding with Category 1 substances when the conditions in its guidance are met. It can remove a substance from Category 1, for example over safety risks. [33, 31]

Outsourcing facilities, FDA-registered compounders of sterile drugs under section 503B, follow separate lists. The FDA’s 503B list, updated March 21, 2025, also places glutathione in Category 1, with a similar policy of not acting when set conditions are met. [34, 35, 36]

In October 2026, HHS, the FDA’s parent department, published a draft policy saying it does not intend to take enforcement action against 503A compounding with six named peptides under set conditions. Glutathione is not one of the six. [37, 38]

The FDA does not approve dietary supplements before they are sold. A supplement must be swallowed, so injected, inhaled and skin products are not supplements. [39]

## Problems with compounded injections

In 2019 the FDA reported seven patients at one clinic who fell ill within minutes of compounded IV glutathione, one needing hospital care. FDA testing found too much bacterial endotoxin, a toxic fragment of bacteria, in the powder used, which was labeled as a dietary supplement. [40]

On August 27, 2026, the FDA reported at least 30 patients with reactions after IV glutathione, alone or mixed with other ingredients. Symptoms included fever, chills, pain, dizziness, signs of shock and symptoms resembling sepsis, a life-threatening response to infection, and some patients were hospitalized. The FDA said these fit too much endotoxin, which can also cause low blood pressure and death, though not all such effects had been reported. The pharmacies involved had all used one lot of glutathione labeled dietary supplement grade. [41]

Four Texas pharmacies recalled glutathione injections for high endotoxin levels between July and October 2026, FDA enforcement records show. The FDA put three of the four recalls in Class I, its most serious class, for products with a reasonable probability of causing serious harm or death. One recalled product was made for injection under the skin; its pharmacy reported two patients who needed emergency care after it was given into a vein. [42, 43, 44, 45]

The CDC reported in September 2026 that over 25 people in at least four states had become sick after glutathione injections into a vein, under the skin or into a muscle. At least three, all given it into a vein, were hospitalized, and one needed intensive care for shock and abnormal blood clotting. So far, every linked injection had been made by a compounding pharmacy from glutathione intended for dietary supplements. [46]

The FDA says compounders should not use supplement-grade ingredients in injectable drugs or rely on testing alone, and advises clinicians to ask their compounders where the glutathione comes from. [41]

## What isn’t known

The long-term safety of IV glutathione is unknown: a 2016 review found no study of its long-term safety, for any purpose. The IV trials described here lasted from a single dose to 6 weeks, or a course of chemotherapy, and the longest swallowed and inhaled trials ran 6 and 12 months. [7, 12, 2, 15, 5, 16]

The 2016 review also warned that shifting skin pigment from brown toward red melanin might make skin more prone to sun damage and skin cancer. It based this on a lab study of pigment cells, not on studies of people taking glutathione. [7]

The FDA’s 2022 review found compounders preparing glutathione for injection under the skin but described no study of that route in people. It found too few animal studies to judge the effects of repeated doses or of exposure during pregnancy and development. [2]

## Questions to ask a clinician

- What would glutathione be meant to do for me, and what evidence supports that use?
- Is there an FDA-approved treatment for my concern, such as melasma?
- Was the glutathione made for injection rather than for dietary supplements, and is each batch tested for sterility and endotoxins?
- Is the product made for the way it will be given, and has its pharmacy had a recall?
- Who would watch for an allergic reaction during an infusion, and how would it be treated?
- Could inhaled glutathione narrow my airways if I have asthma?
- Could glutathione affect my chemotherapy or other medicines?
- Is it known to be safe during pregnancy or breastfeeding?

## Sources

1. Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013. Reference. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/22995213/
2. FDA. Evaluation of glutathione for inclusion on the 503A bulk drug substances list, in the FDA briefing document for the June 8, 2022 meeting of the Pharmacy Compounding Advisory Committee. 2022. Regulator. Checked 2026-11-14. https://www.fda.gov/media/158541/download
3. Witschi A et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/1362956/
4. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/21875351/
5. Richie JP Jr et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/24791752/
6. Watanabe F et al. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women. Clin Cosmet Investig Dermatol. 2014. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/25378941/
7. Davids LM et al. Intravenous glutathione for skin lightening: inadequate safety data. S Afr Med J. 2016. Reference. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/27499402/
8. Hauser RA et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/19230029/
9. Griese M et al. Inhalation treatment with glutathione in patients with cystic fibrosis: a randomized clinical trial. Am J Respir Crit Care Med. 2013. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/23631796/
10. Mischley LK et al. Phase IIb study of intranasal glutathione in Parkinson’s disease. J Parkinsons Dis. 2017. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/28436395/
11. Wahab S et al. Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial. Int J Dermatol. 2021. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/33871071/
12. Wang C et al. Reduced glutathione for prevention of renal outcomes in patients undergoing selective coronary angiography or intervention. J Interv Cardiol. 2015. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/25989827/
13. Jin B et al. Preventive effect of reduced glutathione on contrast-induced nephropathy in elderly patients undergoing coronary angiography or intervention: a randomized, controlled trial. Braz J Med Biol Res. 2015. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/26176313/
14. Wang L et al. Reduced glutathione does not further reduce contrast-induced nephropathy in elderly patients with diabetes receiving percutaneous coronary intervention. J Int Med Res. 2020. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/33243032/
15. Leal AD et al. North Central Cancer Treatment Group/Alliance trial N08CA: the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/24619793/
16. Calabrese C et al. Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros. 2015. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/25458463/
17. Visca A et al. Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 2015. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/25633497/
18. Bozic M et al. Oral glutathione and growth in cystic fibrosis: a multicenter, randomized, placebo-controlled, double-blind trial. J Pediatr Gastroenterol Nutr. 2020. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/32960827/
19. Ciofu O et al. Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019. Systematic review. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/31580490/
20. Smyth JF et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/9261526/
21. Geum MJ et al. Evidence on glutathione and boosters for prevention of chemotherapy-induced neuropathy: a systematic review and network meta-analysis. Basic Clin Pharmacol Toxicol. 2026. Systematic review. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/42876024/
22. Loprinzi CL et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020. Professional guideline. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/32663120/
23. Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/20524875/
24. Weschawalit S et al. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/28490897/
25. Sarkar R et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025. Systematic review. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/39444151/
26. FDA. Injectable skin lightening and skin bleaching products may be unsafe (consumer update first issued in 2015, revised April 19, 2018; archived copy, as the English page is no longer on fda.gov). 2018. Regulator. Checked 2026-11-14. https://web.archive.org/web/20231023195524/https://www.fda.gov/consumers/consumer-updates/injectable-skin-lightening-and-skin-bleaching-products-may-be-unsafe
27. Marrades RM et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med. 1997. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/9279219/
28. FDA. Injectable skin lightening products: what you should know (consumer update, September 2, 2015; archived copy). 2015. Regulator. Checked 2026-11-14. https://web.archive.org/web/20150905135922/http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm460788.htm
29. Milla P et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs. 2009. Trial in people. Checked 2026-11-14. https://pubmed.ncbi.nlm.nih.gov/19287306/
30. FDA. Final summary minutes of the June 8, 2022 meeting of the Pharmacy Compounding Advisory Committee. 2022. Regulator. Checked 2026-11-14. https://www.fda.gov/media/161293/download
31. FDA. Bulk drug substances used in compounding under section 503A of the FD&C Act. 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
32. eCFR. 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. 2026. Regulator. Checked 2026-11-14. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
33. FDA. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act: categories (updated May 14, 2026). 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/media/94155/download
34. FDA. Information for outsourcing facilities. 2022. Regulator. Checked 2026-11-14. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
35. FDA. Bulk drug substances nominated for use in compounding under section 503B of the FD&C Act: categories (updated March 21, 2025). 2025. Regulator. Checked 2026-11-14. https://www.fda.gov/media/94164/download
36. FDA. Bulk drug substances used in compounding under section 503B of the FD&C Act. 2025. Regulator. Checked 2026-11-14. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
37. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, revised November 6, 2026). 2026. Regulator. Checked 2026-11-14. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
38. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526. 2026. Regulator. Checked 2026-11-14. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
39. FDA. Questions and answers on dietary supplements. 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
40. FDA. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables (compounding alert). 2019. Regulator. Checked 2026-11-14. https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables
41. FDA. FDA reminds compounders not to use dietary supplement grade glutathione for injectables (August 27, 2026). 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
42. FDA. Company announcement posted by the FDA: a Texas pharmacy recalls compounded glutathione and two multi-ingredient injections made with a glutathione ingredient with elevated endotoxin (September 2026). 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/centric-compounding-issues-nationwide-recall-glutathione-myers-cocktail-and-tri-immune-boost-due
43. FDA. Company announcement posted by the FDA: a Texas 503A pharmacy recalls compounded glutathione made for injection under the skin over potential elevated endotoxin levels (October 1, 2026). 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/greenwich-rx-issues-voluntary-nationwide-recall-compounded-glutathione-due-elevated-endotoxin-levels
44. FDA. Enforcement reports on 2026 recalls of compounded glutathione injections (openFDA drug enforcement data). 2026. Regulator. Checked 2026-11-14. https://api.fda.gov/drug/enforcement.json?search=product_description:glutathione+AND+report_date:%5B20260101+TO+20261231%5D&limit=100
45. FDA. Recalls background and definitions. 2026. Regulator. Checked 2026-11-14. https://www.fda.gov/safety/industry-guidance-recalls/recalls-background-and-definitions
46. Centers for Disease Control and Prevention. Adverse events linked to injectable glutathione compounded with dietary supplement grade ingredient: current situation (updated September 11, 2026). 2026. Regulator. Checked 2026-11-14. https://www.cdc.gov/healthcare-associated-infections/current-situation/index.html

## Related articles

- [What is NAD+, and what are NMN and NR?](https://roverehealth.com/journal/nad-plus.md): NAD+ is a coenzyme that every cell uses to turn food into energy, and NMN and NR are related molecules the body converts into it. No trial has shown that any of them slows aging in people, a 2026 trial linked NR to worse Parkinson symptoms than placebo, and NAD+ is not FDA-approved for any use.
- [Which peptides can a pharmacy compound?](https://roverehealth.com/journal/which-peptides-can-be-compounded.md): A pharmacy may compound with a raw peptide only if it meets an official quality standard, is in an FDA-approved drug, or is on an FDA list that names no peptide. Peptides that pass none of these, such as BPC-157, can rely at most on nonbinding FDA or HHS policies of not taking action, which are not approvals.
- [What is GHK-Cu, the copper peptide?](https://roverehealth.com/journal/ghk-cu.md): GHK-Cu is a peptide of three amino acids bound to copper, found in human blood and used in skin creams and serums; no drug containing it is FDA-approved. Its few trials in people are small, with mixed results, and none tested injected GHK-Cu on its own, a form the FDA says may provoke immune reactions.
- [What to check when a compounded injection arrives](https://roverehealth.com/journal/checking-a-compounded-injection.md): Check that the package is intact and cold if required, that the label names the pharmacy, patient, drug, strength and a use-by date, and that you know how to measure the dose. Compounded drugs are not FDA-approved, and these checks cannot show whether one is sterile or as strong as its label says.